Clinical Trial

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the investigators are attempting to use T cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR). The CAR enables the T cell to recognize and kill the neuroblastoma cell through the recognition of CD171, a protein expressed of the surface of the neuroblastoma cell in patients with neuroblastoma. This is a phase 1 study designed to determine the maximum tolerated dose of the CAR+ T cells.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2014-12-05; most recent amendment 2026-05-15.
Status change: Recruiting → Active, Not Recruiting 2021-12-13
Trial Details
NCT Number NCT02311621
Lead Sponsor Seattle Children's Hospital
Collaborators: The Evan Foundation, Ben Towne Center for Childhood Cancer Research
Conditions Neuroblastoma, Ganglioneuroblastoma
Enrollment 65 participants
Start Date 2014-11-25
Primary Completion 2023-11 (estimated)
Study Completion 2038-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-19